NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free AUTL Stock Alerts $4.39 +0.32 (+7.86%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.39▼$4.8450-Day Range$3.68▼$6.5552-Week Range$2.01▼$7.45Volume2.03 million shsAverage Volume2.35 million shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$8.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Autolus Therapeutics alerts: Email Address Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside98.2% Upside$8.70 Price TargetShort InterestHealthy1.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.44 out of 5 starsMedical Sector293rd out of 918 stocksBiological Products, Except Diagnostic Industry39th out of 152 stocks 3.4 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.32% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 13.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.6 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressHow this is some devastating newsCheck out this report real quick… It’s full proof that most people barely have enough money to cover the monthly expenditures… Let alone save for retirement or plan the next vacation. At the risk of sounding political… If you’re waiting for the Fed, or the government or some financial advisor to come to change things for the better… You might be waiting for a long long time. But what if…? What if there was a way to completely turn the tables?But I can promise that you’ll see all the details for yourself here. About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesMay 18 at 7:06 AM | finance.yahoo.comQ1 2024 Autolus Therapeutics PLC Earnings CallMay 17 at 3:37 PM | investorplace.comAUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024May 17 at 11:00 AM | finance.yahoo.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 17 at 7:00 AM | globenewswire.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 16 at 12:58 PM | markets.businessinsider.comHere's what to expect from Autolus Therapeutics's earnings reportMay 14, 2024 | seekingalpha.comAutolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An OpportunityMay 14, 2024 | globenewswire.comAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | finance.yahoo.comAutolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallApril 27, 2024 | wsj.comAutolus Therapeutics Ltd. ADRApril 25, 2024 | finance.yahoo.comRecent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 yearApril 24, 2024 | globenewswire.comAbstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCOApril 23, 2024 | globenewswire.comAutolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 21, 2024 | nasdaq.comRSI Alert: Autolus Therapeutics (AUTL) Now OversoldApril 12, 2024 | markets.businessinsider.comBuy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive OutlookApril 9, 2024 | investing.comTruist raises Autolus Therapeutics stock target on market lead potentialApril 2, 2024 | finance.yahoo.comAutolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)April 1, 2024 | globenewswire.comAutolus Therapeutics Announces Changes to its Board of DirectorsMarch 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday TradingMarch 18, 2024 | markets.businessinsider.comBreaking Down Autolus Therapeutics: 4 Analysts Share Their ViewsMarch 17, 2024 | finance.yahoo.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-celMarch 15, 2024 | finance.yahoo.comQ4 2023 Autolus Therapeutics PLC Earnings CallMarch 15, 2024 | finance.yahoo.comAutolus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 15, 2024 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 15, 2024 | msn.comAutolus Therapeutics FY 2023 Earnings PreviewSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees463Year FoundedN/APrice Target and Rating Average Stock Price Target$8.70 High Stock Price Target$11.00 Low Stock Price Target$4.80 Potential Upside/Downside+98.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-208,380,000.00 Net MarginsN/A Pretax Margin-12,273.38% Return on Equity-105.75% Return on Assets-49.25% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio6.15 Sales & Book Value Annual Sales$1.70 million Price / Sales686.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book6.86Miscellaneous Outstanding Shares265,930,000Free Float197,583,000Market Cap$1.17 billion OptionableOptionable Beta2.03 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 60)CEO & Director Comp: $2.39MDr. Martin Pule M.D. (Age 52)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Robert F. Dolski (Age 53)Senior VP & CFO Mr. Christopher Vann (Age 59)Senior VP & COO Mr. David Brochu (Age 68)Senior VP & Chief Technical Officer Mr. Alexander Swan (Age 59)Senior VP & Chief Human Resources Officer Mr. Brent Rice (Age 58)Senior VP, Chief Commercial Officer & Site Head of US Ms. Olivia ManserDirector of Investor RelationsMr. Alex DriggsSenior VP of Legal Affairs & General Counsel and SecretaryDr. Chris Williams (Age 44)Senior VP & Chief Business Development Officer More ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXScholar RockNASDAQ:SRRKCullinan OncologyNASDAQ:CGEMImmaticsNASDAQ:IMTXProKidneyNASDAQ:PROKView All CompetitorsInstitutional OwnershipB. Riley Wealth Advisors Inc.Bought 17,000 shares on 5/16/2024Ownership: 0.006%Bayesian Capital Management LPBought 15,600 shares on 5/16/2024Ownership: 0.006%Affinity Asset Advisors LLCBought 1,824,592 shares on 5/15/2024Ownership: 1.269%Bellevue Group AGSold 17,500 shares on 5/15/2024Ownership: 0.012%Lazard Asset Management LLCSold 4,179 shares on 5/15/2024Ownership: 0.003%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price target for 2024? 5 brokerages have issued twelve-month price objectives for Autolus Therapeutics' stock. Their AUTL share price targets range from $4.80 to $11.00. On average, they expect the company's stock price to reach $8.70 in the next year. This suggests a possible upside of 98.2% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2024? Autolus Therapeutics' stock was trading at $6.44 at the start of the year. Since then, AUTL stock has decreased by 31.8% and is now trading at $4.39. View the best growth stocks for 2024 here. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. What ETFs hold Autolus Therapeutics' stock? ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Alger 35 ETF (ATFV).Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (4.64%), Price T Rowe Associates Inc. MD (2.06%), Affinity Asset Advisors LLC (1.27%), Perpetual Ltd (0.84%), BNP Paribas Financial Markets (0.04%) and Capstone Investment Advisors LLC (0.03%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUTL) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
